InveniAI® reports the appointment of Salvatore (Salvo) Alesci, M.D., Ph.D., as its Chief Scientific Officer.
Dr. Alesci, a physician-scientist, R&D strategist, and science policy influencer with expertise in translational medicine, will be responsible for advancing programs from IND-enabling to human proof-of-concept studies.
more
|
|
|
|